![Servier - Moved by you..]({"type":"image" , "src" : "/sda/112354/JournalAd-Servier-5s.gif"})
References
- Mohsen A, Jimenez A, Dickfeld T, Saliaris A, Kuk R, Shorofsky 5, Saba M. Under-diagnosis of cardiac sarcoidosis using the original Japanese Ministry of Health and Welfare criteria. Circulation 2010; 122(21 suppl 4): A[20962].
- Aviles R, Martin D, Apperson-Hansen C, Houghtaling P. Rautaharju P. Kronmal R, Tracy R, Van Wagoner D, Psaty B, Lauer M, Chung M. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006–10.
- Winters SL, Cohen M, Greenberg Stein B, Curwin J, Pe E, Gomes J. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18:937–43.
- Chiu CZ, Nakatani 5, Zhang G, Tachibana T, Ohmori F, Yamagishi M, Kitakaze M, Tomoike H, Miyatake K. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95:143–6.
- Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, Ogo KO, Nishii N, Watanabe A, Nagase 5, Sakuragi 5, Ohe T. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 2007; 4: 1292–9.
![Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.]({"type":"image" , "src" : "/sda/112387/JournalAd-TACD-BOEHR-MPU.jpg"})
![A bold vision to stop cardiovascular disease from being a leading cause of death.]({"type":"image" , "src" : "/sda/112402/JournalAd-amarin.jpg"})